

# Improving parenchymal phase imaging of the pancreas with multidetector CT using experience from dynamic contrast enhanced MR studies.

<b>Submission date</b> 29/09/2006	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 29/09/2006	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 15/05/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Nandita De Souza

### Contact details

Clinical Magnetic Resonance  
The Royal Marsden NHS Foundation Trust  
Downs Road  
Sutton  
United Kingdom  
SM2 5PT  
+44 (0)20 8661 3289  
[nandita.desouza@icr.ac.uk](mailto:nandita.desouza@icr.ac.uk)

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N0258161818

# Study information

## Scientific Title

## Study objectives

To improve the diagnosis of pancreatic cancer by exploiting technology available on newer CT scanners to improve the enhancement of normal pancreatic tissue.

As of 15/05/2012, the anticipated end date for this trial has been updated from 18/04/2006 to 30/06/2006.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Cancer: Pancreatic

## Interventions

Randomised test intervention vs standardised intervention, non-blinded (Phase III)

## Intervention Type

Other

## Phase

Phase III

**Primary outcome measure**

1. Absolute value of the Hounsfield attenuation in normal pancreatic tissue at pancreatic parenchymal phase.
2. Clinical radiologist's impression on the utility/benefit of mucosal enhancement of adjacent duodenum in aiding local staging.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

19/09/2005

**Completion date**

30/06/2006

**Reason abandoned (if study stopped)**

Lack of staff/facilities/resources

## **Eligibility**

**Key inclusion criteria**

1. Age over 18 - pancreatic adenocarcinoma is unusual below this age and children are more sensitive to additional ionising radiation than adults
2. Stage III ovarian cancer or colorectal cancer
3. Routine attendance for contrast enhanced abdominal CT - no patients not otherwise having CT and contrast will be approached.

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

60

**Key exclusion criteria**

1. Severe local disease affecting pancreatic aorta/branches. This may introduce delays to the arrival of contrast due to compromise of arteries (SMA/Coeliac axis)
2. Major atherosclerotic disease of SMA/Coeliac axis - again, to avoid significant delay in contrast path distal to pancreatic aorta
3. Significant pancreatic resection - absence of normal pancreatic tissue will preclude our

numerical assessment of enhancement

4. Pre-existing pancreatic disease - cancer or pancreatitis.

**Date of first enrolment**

19/09/2005

**Date of final enrolment**

30/06/2006

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Clinical Magnetic Resonance**

Sutton

United Kingdom

SM2 5PT

## **Sponsor information**

**Organisation**

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

**Sponsor details**

The Department of Health, Richmond House, 79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

**Sponsor type**

Government

**Website**

<http://www.dh.gov.uk/Home/fs/en>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

The Royal Marsden NHS Foundation Trust

**Funder Name**

NHS R&D Support Funding

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration